PPT-Unique botanically-based pharmaceutical solutions

CORPORATE PRESENTATION Pharmaceuticals Q4 2017 This presentation contains forwardlooking statements as that term is defined in the Private Securities Litigation Reform Act of 1995 For this purpose any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forwardlooking statements Without limiting the generality of the foregoing words such as may will to plan expect believe anticipate intend could should would estimate or continue or the negative or other variations thereof or comparable terminology are intended to identify forwardlooking statements Shareholders are cautioned that all forwardlooking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements Such risks and uncertainties include but are not limited to the following the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved government regulation generally competitive developments the ability to successfully market products domestically and internationally difficulties or delays in manufacturing or issues relating to manufacturing capacity commercial obstacles to the successful introduction of brand products generally legal defense costs insurance expenses settlement costs and the risk of an adverse decision or settlement relating to product liability patent protection governmental investigations and other legal proceedings the Companys ability to acquire and protect patents and other intellectual property both domestically and internationally the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals any changes in business political and economic conditions business interruption due to hurricanes or other events outside of the Companys control. Matravers. Vice President Product Development. The Difference is. Pure, Safe, Beneficial. ™. Our Brand. a . premium brand with a Swiss heritage. . products . that are healthy, botanically based, . . BY. Dr. RAJESH KUMAR SINGH. Associate Professor. Delhi Technological University (DCE), Delhi. . 1. Plan of Presentation. Introduction of Pharmaceutical Industry. The Global pharmaceutical industry-part-2. The Framework of five forces.. Potential entrants. Substitutes. Buyers. Suppliers. Implication of the five forces. Potentials entrants “Treat of entry”. . . Presented by. Ma . Shiao. Lin. MBA IV ,59 . The Brookings Institution • . Washington, DC. Monday, October 19. th. , 2015. Promoting the Adoption of . Advanced . Manufacturing in the Pharmaceutical Industry: the FDA . Perspective. . Promoting Continuous Manufacturing in the Pharmaceutical Sector. sector. . Cécile . Macé. Department of Essential Medicines and Health Products. English Technical Briefing Seminar. 30 October 2013. Ten leading causes of inefficiency. World Health Report 2010, Chapter 4. . A Prescription for Saving$. . What is the Statewide Pharmaceutical Program (SPP)?. Administered by the California Department of General Services (DGS), Pharmaceutical Acquisitions Section. Created by Government . Prof.. Viswanath Pingali. Indian Institute of Management Ahmedabad. 29-03-2013. 1. Preliminaries. Please organize yourselves into groups of five, preferably not from the same background. 29-03-2013. Litiahina. . Mariia. DIPLOMA PROJECT. . The topicality of the problem is . connected with the fact that the pharmaceutical market today is one of the most promising and fastest growing markets in the economy of Ukraine.. Curtis Smith. November 30, . 2016. Big Data Panel Discussion. Big . Data and the Pharmaceutical Industry. 2. There has been substantial change to the . Pharmaceutical data . environment over the last 5 years. . March 27th 2014, University of Zurich . Fabienne Heimgartner, Interpharma. What. . it. . needs. . for. . one. . drug. CHF . investment. working. . hours. . experiments. scientists. drug. 1 000 000 000. sector. . Cécile . Macé. Department of Essential Medicines and Health Products. English Technical Briefing Seminar. 30 October 2013. Ten leading causes of inefficiency. World Health Report 2010, Chapter 4. . АК «Узфармсаноат». Pharmaceutical industry of Uzbekistan. O` z f a r m s a n o a t. www.uzpharmsanoat.uz. Manufacturers of medical devices- - . 4. 6. Manufacturers of diagnostic tools- - . INGREDIENTS AND EXCIPIENTS DEFINITIONS . AND . TYPES. Lec. Dr . Athmar. . Dhahir. . habeeb. PhD in industrial pharmacy and pharmaceutical formulations . To . produce a drug substance in a . final dosage .